Juniper Pharmaceuticals, Inc. Common Stock
JNP
JNP was delisted on the 13th of August, 2018.
31 hedge funds and large institutions have $18.2M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 6 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
6% less funds holding
Funds holding: 33 → 31 (-2)
8% less capital invested
Capital invested by funds: $19.8M → $18.2M (-$1.66M)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $51K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$390K |
| 2 |
Renaissance Technologies
New York
|
+$230K |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$133K |
| 4 |
AG
Algert Global
San Francisco,
California
|
+$115K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$82.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$505K |
| 2 |
Morgan Stanley
New York
|
-$112K |
| 3 |
Goldman Sachs
New York
|
-$110K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$87.2K |
| 5 |
SIM
Spark Investment Management
New York
|
-$66.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $31K | +$122 | +26 | +0.4% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $14K | +$11.3K | +2,414 | +431% |
|
28
Simplex Trading
Chicago,
Illinois
| $6K | +$6.75K | +1,437 | New |
|
29
UBS Group
Zurich,
Switzerland
| $1K | -$9.66K | -2,058 | -94% |
|
|
FWM
30
Focused Wealth Management
Newburgh,
New York
| $1K | – | – | – |
|
|
AIC
31
AWM Investment Company
New York
| – | -$505K | -100,000 | Closed |
|
|
32
Goldman Sachs
New York
| – | -$110K | -21,735 | Closed |
|
|
TC
33
TFS Capital
West Chester,
Pennsylvania
| – | -$83K | -16,490 | Closed |
|
|
AIM
34
Acrospire Investment Management
Chicago,
Illinois
| – | -$43K | -8,423 | Closed |
|
35
Envestnet Asset Management
Chicago,
Illinois
| – | -$4.7K | -1,000 | -100% |
|
36
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$2K | -386 | Closed |
|
JNP Hedge Fund Activity: Q3 2017 in Review
31 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q3 2017, worth a combined $18.2M — down 8.4% from $19.8M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of JNP and 4 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 9 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $390K. The largest seller was AWM Investment Company, exiting entirely with an estimated $505K sold.
- 31 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q3 2017, down from 33 in Q2 2017.
- Funds reported $18.2M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q3 2017, down 8.4% quarter-over-quarter.
- 4 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q3 2017 and 6 closed out, a net change of -2 holders.
- The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q3 2017 was Bridgeway Capital Management, an estimated $390K added.
- The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q3 2017 was AWM Investment Company, an estimated $505K sold.
Based on aggregated 13F filings for Q3 2017.